CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations

  • STATUS
    Recruiting
  • participants needed
    21
  • sponsor
    Cytovation AS
Send
Updated on 19 February 2024
See if I qualify

Summary

This Phase I/IIa trial is designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of CyPep-1 when administered directly into malignant tumors. Additionally, the trial will monitor anti-tumor effects on both injected lesions and distant non-injected deposits.

Description

Treatment with immune modulating agents may result in long lasting anti-tumor responses in patients with cancer. However, only a subset of patients obtains durable remission. Treatment strategies that aim at recruiting tumor antagonizing cellular components of the immune system holds great promise. CyPep-1 is a chemically synthesized peptide with oncolytic properties. It selectively targets cancer cells based on their altered molecular composition, and removes the surrounding cell membrane. This releases tumor neoantigens to the microenvironment and potentially induces an anti-tumour immune response.

This is a phase I/IIa dose escalation study to evaluate the safety and tolerability of CyPep-1 and identify the recommended phase 2 dose. Secondary objectives are preliminary anti-tumor efficacy and to assess the pharmacokinetics (PK) of CyPep-1

Details
Condition Advanced Solid Tumor Malignancy
Age 18-100 years
Treatment CyPep-1
Clinical Study IdentifierNCT04260529
SponsorCytovation AS
Last Modified on19 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

Histologically confirmed diagnosis of advanced (unresectable Stage III) or metastatic (Stage IV) solid tumor malignancy (including lymphomas) that is refractory to standard-of-care treatment or for which there is no standard therapy considered appropriate. Metastatic deposits (including cutaneous/subcutaneous lesions and metastatic deposits in lymph nodes) of tumors for which IT injections may be performed are eligible. Pure cutaneous infiltrations (e.g., breast cancer cutaneous carcinomatosis) are ineligible
1 to 3 non-ulcerated transcutaneously accessible lesion(s) for injection and measurable as defined by iRECIST v1.1. All other tumor lesion(s) may be selected for efficacy follow-up, but will not be subjected to treatment with CyPep-1
Presence of tumor lesion(s) (that have not been previously irradiated) suitable for biopsy at screening and at Week 6, among which one target lesion for CyPep-1 treatment is mandatory and if possible, also one non-injected lesion
Age 18 years
Estimated life expectancy of at least 3 months
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 (Appendix B)
Resolution of toxicity due to prior therapy to Grade < 2 (except for alopecia and transaminases in case of liver metastases) as defined by CTCAE v5.0
Ability to give written informed consent and to comply with the protocol
All subjects of childbearing potential (defined as < 2 years after last menstruation or not surgically sterile) must have a negative high sensitive pregnancy test at screening (urine/serum) and agree to use highly effective method for contraception according to the EU Clinical Trial Facilitation Group guidance from time of signing Informed Consent until at least 120 days after the last administration of CyPep-1. The partners of subjects with childbearing potential must also apply contraceptive methods and are recommended not to donate sperm
Adequate bone marrow, liver, and renal function
Platelet count 100 x 109/L
Hemoglobin 6.0 mmol/L or 9.67 g/dL
Absolute Neutrophil Count (ANC) 1.5 x 109/L
Total bilirubin 1.5 x ULN, except for subjects with familial bilirubinemia (Gilbert's disease)
Serum ASAT and ALAT 2.5 x ULN ( 5 x ULN in case of liver metastases)
Creatinine clearance 30 mL/min (by Cockcroft-Gault formula)

Exclusion Criteria

There is no limit to the number of prior treatment regimens, but prior treatment(s) should not include compounds delivered by IT injection, including investigational agents
Participation in another clinical trial within 4 weeks prior to first dose of CyPep-1
Anti-cancer therapy within 4 weeks prior to the first dose of CyPep-1 (within 2 weeks for palliative radiotherapy, within 1 week for endocrine therapy)
Major surgical procedure within 14 days prior to the first dose of CyPep-1
Live vaccine within 30 days prior to first dose of CyPep-1
Expected to require any other form of systemic or localized antineoplastic therapy while in this trial. Localized palliative radiotherapy for pain relieve is allowed on tumor lesions that are not selected for evaluation of treatment response
Clinical evidence of an active second malignancy that is progressing or requires active treatment, except for curatively treated early stage (carcinoma in situ or stage 1) carcinomas or non-melanoma skin cancer
Active autoimmune disease requiring immunosuppressive therapy
Any condition requiring continuous systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive agents within 2 weeks prior to first dose of CyPep-1. Inhaled, intranasal or topical (only on areas outside the target lesion(s)) and physiological replacement doses of up to 10 mg daily prednisone equivalent are permitted in the absence of active auto-immune disease
Abnormal or clinically significant coagulation parameters at the discretion of the investigator, i.e
Prothrombin Time - International Normalized Ratio (PT-INR)
Activated Partial Thromboplastin Time (APTT) Subjects being treated with anticoagulants are excluded if the coagulation parameters are outside the therapeutic intervals as described in the SmPC for the administered treatment
Subjects on anticoagulants for whom temporarily stop and start, supported by low molecular weight heparin (or other anticoagulation therapy at the discretion of the investigator and/or per local standard of care) during treatment period, is not an option
Past history of severe allergic episodes and/or Quincke's edema
Known hypersensitivity to any component of CyPep-1
Prior allogeneic tissue/solid organ transplant, stem cell or bone marrow transplant
Known active human immunodeficiency virus (HIV). Subject is eligible when normal levels of CD4 are present
Central nervous system (CNS) metastasis that is symptomatic or progressing or that requires current therapy (e.g., evidence of new or enlarging CNS metastasis or new neurological symptoms attributable to CNS metastasis)
QTcF > 480 ms, history of long or short QT syndrome, Brugada syndrome, or known history of QTc prolongation, or Torsade de Pointes
Women who are pregnant or breastfeeding
Any serious and/or unstable pre-existing medical, psychiatric or other condition which in the investigator's opinion could interfere with subject safety, obtaining written informed consent, or compliance with the trial protocol
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.